One of the biggest challenges payers face today is the impact of innovative, new therapies for diseases with unmet needs (oncology & rare diseases). These new therapies show promise but there is often significant uncertainty regarding their added value to patients and cost to the health care system. In other cases, the new therapies front load most of the cost to the beginning of care. This has created strain on healthcare system budgets, raising affordability and equity issues, and creating a great deal of uncertainty for assessment bodies and payers order to address the high upfront costs of curative therapies. A potential solution to address these concerns is the development of performance-based managed entry agreements.

ISPOR will host the ISPOR Payer Summit on April 22, 2021. This multi-stakeholder working meeting includes payers, HTA bodies, manufacturers, CROs, academia, and patient representatives. This spotlight session will summarize the findings from the summit and explore the challenges and benefits of performance based MEAs. Hearing different perspectives from the stakeholders defining the points of convergence (or agreement) and working to align the differences related MEAs is critical to achieve optimum patient access.